Join our daily newsletter At The Bell to receive exclusive market insights
- MGC Pharmaceuticals’ (MXC) distribution partner, AMC Holdings, orders an initial 1000 units of CimetrA to fast track the approvals process in the US
- AMC will see the units shipped to a pharmacy in Tampa where they’ll be analysed to make comparisons with MGC Pharma’s research lab in Slovenia
- Meanwhile, AMC is working with the University of South Florida and the Holy Cross Hospital to submit CannEpil and CogniCann to their review boards
- Both parties maintain they are on track to meet the key conditions of the agreement
- MGC Pharmaceuticals has ended the day 5.17 per cent in the green to close at 6.1 cents
MGC Pharmaceuticals’ (MXC) distribution partner, AMC Holdings, has fast tracked US sales through an initial order for 1000 units of CimetrA.
Under a supply and distribution agreement signed in August, AMC has now formally submitted its first order on an expedited basis. The units will be shipped to a pharmacy in Tampa area where they’ll be analysed to make comparisons with MGC Pharma’s research lab in Slovenia.
CimetrA is a proposed treatment for the disease associated with SARS-CoV-2, including Cytokine Storm, a severe symptom of COVID-19.
The agreement also requires AMC to establish clinical trials for both of MGC Pharma’s other drugs, CannEpil and CogniCann.
AMC has been working with both the University of South Florida in Tampa and the Holy Cross Hospital in Fort Lauderdale to submit its two treatments to their respective internal review boards.
The approval from these boards will be the first step for both facilities to join the clinical trials which are underway in Israel, and to launch US based clinical trials.
MGC Pharma, CEO and Managing Director, Roby Zomer, commented on the progress.
“AMC are already making significant progress in propelling CimetrA, CannEpil and CogniCann to clinical trial stage in the US and we are pleased that they have cemented relationships with these prestigious institutions for the continued research into our products.”
Both parties maintain they are on track to meet the key conditions of the agreement.
MGC Pharmaceuticals ended the day 5.17 per cent in the green to close at 6.1 cents.
